Status:

COMPLETED

Mirtazapine Versus Placebo in Functional Dyspepsia

Lead Sponsor:

Universitaire Ziekenhuizen KU Leuven

Conditions:

Functional Dyspepsia

Eligibility:

All Genders

18-75 years

Phase:

PHASE4

Brief Summary

Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg daily or placebo, followed by 8 weeks of open-label mirtazapine 15 mg daily

Detailed Description

Double-blind randomized controlled trials of 8 weeks mirtazapine 15 mg or placebo, followed by 8 weeks of open-label mirtazapine Two weeks run-in, 8 weeks randomized, 8 weeks open label Assessments ...

Eligibility Criteria

Inclusion

  • Functional dyspepsia according to Rome II criteria
  • Weight loss of \> 5% body weights

Exclusion

  • Organic GI pathology
  • History of upper gi tract surgery
  • Major depression or anxiety
  • Use of antidepressants in the last 2 months
  • Prokinetic drugs or spasmolytic drugs
  • Analgesic use (except paracetamol)
  • Pregnancy or lactation

Key Trial Info

Start Date :

September 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 11 2012

Estimated Enrollment :

35 Patients enrolled

Trial Details

Trial ID

NCT01240096

Start Date

September 1 2006

End Date

September 11 2012

Last Update

July 1 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals

Leuven, Flanders, Belgium, 3000